GlassScriptPhysician profile
Vinay Puri
NPI 1275531345
$195,398.43
in general payments reported to CMS, 2019-2025
17 companies · $25K in 2025
The $25K reported for 2025 was more than what 95% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $16K · 2021: $21K · 2022: $28K · 2023: $54K · 2024: $36K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Consulting Fee: $14K · Travel and Lodging: $14K · Food and Beverage: $2,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,073.00 |
| Consulting Fee | $14,168.00 |
| Travel and Lodging | $13,558.39 |
| Food and Beverage | $2,811.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $153,808.24 | 2020-2025 | Valtoco |
| Eisai INC. | $25,456.15 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $13,462.38 | 2025 | Daybue |
| Zogenix INC. | $1,000.00 | 2020 | |
| Supernus Pharmaceuticals, INC. | $444.32 | 2019-2021 | |
| Ucb, INC. | $350.52 | 2019-2025 | Briviact, Fintepla |
| Jazz Pharmaceuticals INC. | $184.98 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $167.12 | 2019 | |
| Travere Therapeutics, INC. | $157.23 | 2019 | |
| Livanova USA, INC. | $139.06 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Dixi Medical USA Corp | $103.34 | 2023 | |
| Sarepta Therapeutics, INC. | $59.07 | 2019-2024 | Elevidys |
| Biocodex, INC. | $25.53 | 2023 | Diacomit |
| Novartis Pharmaceuticals Corporation | $23.08 | 2019 | |
| Ptc Therapeutics, INC. | $17.41 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.